SLXN (Silexion Therapeutics) Preferred Stock: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLXN Silexion Therapeutics Corp SLXN
13 GF Score
Price $0.37
! 1 Warning Sign
View Full Analysis

What is Silexion Therapeutics Preferred Stock?

Silexion Therapeutics SLXN +0.73% 13 Preferred Stock is $0.00 Mil as of Jun. 2026. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. Silexion Therapeutics's preferred stock for the quarter that ended in Jun. 2026 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Silexion Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $1.01 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Silexion Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $0.04.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Silexion Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-5.17.


Silexion Therapeutics  (NAS:SLXN) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Silexion Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Silexion Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Silexion Therapeutics's Earnings per Share (Diluted) (EPS) for the three months ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silexion Therapeutics Preferred Stock Related Terms


Silexion Therapeutics Preferred Stock Historical Data

* Premium members only.

The historical data trend for Silexion Therapeutics's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silexion Therapeutics Preferred Stock Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Preferred Stock
0.00 0.00 0.00 0.00

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SLXN
13GF Score
Silexion Therapeutics Corp SLXN
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silexion Therapeutics Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of $0.00 Mil mean?
Silexion Therapeutics (SLXN) has a Preferred Stock of $0.00 Mil as of Jun. 2026. Preferred Stock represents the par value of a company's preferred shares. View historical data on Silexion Therapeutics and its competitors.
Is Silexion Therapeutics' Preferred Stock too high?
Silexion Therapeutics' current Preferred Stock is $0.00 Mil. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Preferred Stock compare to DCOY and VRAX?
Silexion Therapeutics' Preferred Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Silexion Therapeutics and its competitors. Silexion Therapeutics's current Preferred Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Preferred Stock of $0.00 Mil. The current Preferred Stock is $0.00 Mil. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Preferred Stock is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Silexion Therapeutics Business Description

Address 12 Abba Hillel Road, Ramat-Gan, ISR, 5250606
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score

Get the complete analysis for SLXN

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price